HRS-5041 clinical trials
Also written HRS-5041.
How each study uses HRS-5041 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-5041 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Jiangsu HengRui Medicine Co., Ltd. (3) · Atridia Pty Ltd. (2) · Fudan University (1) · Hansoh BioMedical R&D Company (1)
Often tested with
Tested in the same studies.
HRS-2189 (1) · Prednisone acetate (1) · Prednisone (1) · HRS-6208 (1) · Risvutatug rezetecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test HRS-5041.
- Dec 2026A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
- Dec 2026A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate CancerPhase 1 · Atridia Pty Ltd.
- Jan 2027Study of HRS-2189 Combined HRS-5041 in Prostate CancerPhase 2 · Fudan University
Studies
Open first, then newest update. How each study uses HRS-5041 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06568094Written as HRS-5041 tablets
- Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05942001Written as HRS-5041
- Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate CancerRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT07115446Written as HRS-5041
- Study of HRS-2189 Combined HRS-5041 in Prostate CancerNot yet recruitingPhase 2Fudan UniversityNCT06738745Written as HRS-5041
- A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 1Atridia Pty Ltd.NCT06830850Written as HRS-5041 Single dose of HRS-5041 orally administered
- A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT07014488Written as HRS-5041 Tablets
- Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male ParticipantsCompletedPhase 1Atridia Pty Ltd.NCT06559007Written as HRS-5041 dose level 1